Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study
Authors:
- Peter KenemansPKPeter Kenemans
- Christof SohnCSChristof Sohn
- Peter KristenPKPeter Kristen
- Gerhard CrombachGCGerhard Crombach
- Volker MöbusVMVolker Möbus
- Manfred KaufmannMKManfred Kaufmann
- Hans CafierHCHans Cafier
- Peter Schmidt-RhodePSPeter Schmidt-Rhode
- Rolf KreienbergRKRolf Kreienberg
Open Access
Abstract
Background. In a prospective study, the differential dignostic potential of peovic examination, ultrasound, and serum CA 125 assay in postmenopausal patients presenting with a pelvic mass was assessed. Methods. A total of 228 patients were evaluated preoperatively in an international, multicenter, prospective study using a standard protocol for pelvic examination, transvaginal (occasionally additional abdominal) ultra sound, and serum CA 125 determination with a cut‐off level of 35 U/ml. Results. Ninety‐five malignant (41.7%) and 127 benign (55.7%) pelvic tumors were found in addition to 6 borderline ovarian tumors (2. 6%) in the 228 patients. Seventy‐two patients had ovarian carcinoma, 49 of whom were International Federation of Gynecology and Obstetrics Stage III or IV. Borderline tumors were excluded from the statistical calculations. The individual accuracy of pelvic examination, ultrasound, and serum CA 125 in discriminating between benign and malignant pelvic masses was approximately the same (76, 74, and 77%, respectively). Using logistic regression analysis, the power of pelvic examination appeared to be the most relevant factor (adjusted odds ratio, 9. 2), followed by serum CA 125 (odds ratio, 5. 6), and ultrasound (odds ratio, 4. 9). Age appeared to be nonpredictive. No cancer was found in any patient in whom all three methods scored negative (n = 53; positive predictive value for malignancy = 0 and 95%; confidence interval, 0–7). Conclusions. The combined use of pelvic examination, ultrasound, and serum CA 125 leads to improved discrimination between malignant and benign pelvic masses, because malignancy can be excluded when all three examination methods are negative. A change to a more patient‐tailored surgical approach could be considered in those cases.Keywords
This publication has 28 references indexed in Scilit:
- Risk Factors and a Risk Scoring System for the Prediction of Malignancy in Ovarian CystsAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1992
- Sialyl-Tn, Sialyl-Lewis Xi, CA 19-9, CA 125, Carcinoembryonic Antigen, and Tissue Polypeptide Antigen in Differentiating Ovarian Cancer From Benign TumorsObstetrics & Gynecology, 1992
- Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab′)2: pharmacokinetics, tissue distribution, and tumor imagingInternational Journal of Gynecological Cancer, 1992
- Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: Relevance for differential diagnosisGynecologic Oncology, 1990
- Tumors in the lower pelvis as imaged by vaginal sonographyGynecologic Oncology, 1990
- Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer.BMJ, 1989
- Simple adnexal cysts diagnosed by ultrasound in postmenopausal womenJournal of Clinical Ultrasound, 1988
- Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assaysInternational Journal of Cancer, 1988
- Evaluation of Serum CA125 Values in Healthy Individuals and Pregnant WomenThe American Journal of the Medical Sciences, 1986
- DISTINCTION OF BENIGN FROM MALIGNANT OVARIAN CYSTS BY ULTRASOUNDBJOG: An International Journal of Obstetrics & Gynaecology, 1978